Skip to main content
Delfa

← All assets

NS101

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

1

Recruiting

0

Completed

0

Sites

0

Countries

0

Endpoints

12

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 12 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1

Trials by status

Not yet recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)
4
Executive function / language
3
Safety / tolerability / PK
2
Function / daily living
1
Neurodegeneration biomarkers
1
Neuroimaging
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 2 of 12 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neurofilament light (NfL)Neurodeg.

1

ADCS-Activities of Daily Living (ADCS-ADL)Function

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT07154485Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

NS101

Frontotemporal dementia

Amyloid biomarker required (PET/CSF)Ph 2Not yet recruiting0Aug 2027-

Showing 1-1 of 1 trials